StockData
Merck & Co., Inc. logo

Merck & Co., Inc.

MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30250% above fair value
$149.52+3.19 (+2.18%)

Close on Oct 30, 2026Market cap $368.89BP/E 119.6Yield 2.19%

Merck Pharmaceutical Sales by Quarter

Pharmaceutical Sales — Asia Pacific (other than China and Japan) ($M) ($M)

QuarterlyAnnual

Merck Pharmaceutical Sales: $636M in Q2 2026, up 4.4% from a year earlier.

Latest, Q2 2026
636
Period ended Jun 30, 2026
Change on a year earlier
+4.4%
609 in Q2 2025
History
30 quarters
Since Q1 2019
Sources
11
Documents cited below

Where the Q2 2026 figure comes from

“|| Asia Pacific (other than China and Japan) | 569 | 636 | 1,205 | 535 | 609 | 1,144 | 593 | 586 | 2,323 | 5 | 5”

Source: Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗

Reported in Form 8-K Supplemental Table 3c / 3b (Pharmaceutical Geographic Sales).

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedPharmaceutical Sales — Asia Pacific (other than China and Japan) ($M) ($M)Year on yearSource
Q2 2026Jun 30, 2026636+4.4%Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Q1 2026Mar 31, 2026569+6.4%Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Q4 2025Dec 31, 2025586-4.2%Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Q3 2025Sep 30, 2025593-11.4%Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Q2 2025Jun 30, 2025609+2.4%Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Q1 2025Mar 31, 2025535-7.8%Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Q4 2024Dec 31, 2024612-0.6%Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
Q3 2024Sep 30, 2024669+5.2%Form 8-K (tm2529620d1_ex99-1.htm, filed 2025-10-30) ↗
Q2 2024Jun 30, 2024595-15.6%Form 8-K (tm2529620d1_ex99-1.htm, filed 2025-10-30) ↗
Q1 2024Mar 31, 2024580-17.5%Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
Q4 2023Dec 31, 2023616-10.9%Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗
Q3 2023Sep 30, 2023636-9.4%Form 8-K (tm2426878d1_ex99-1.htm, filed 2024-10-31) ↗
Q2 2023Jun 30, 2023705-17.4%Form 8-K (tm2426878d1_ex99-1.htm, filed 2024-10-31) ↗
Q1 2023Mar 31, 2023703-10.6%Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗
Q4 2022Dec 31, 2022691+41.6%Form 8-K (tm244517d1_ex99-1.htm, filed 2024-02-01) ↗
Q3 2022Sep 30, 2022702+56.0%Form 8-K (tm2328962d1_ex99-1.htm, filed 2023-10-26) ↗

Breakdown

What makes up pharmaceutical Sales

Cite this data

StockData. (2026). Merck Pharmaceutical Sales ($M), quarterly Q1 2019–Q2 2026 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/pharma-geo-asiapacific-excnjp

See every metric in the Merck KPI table. Data updated Oct 26, 2026.